Revvity reported stronger-than-expected second-quarter results, driven by improving customer demand and higher profitability, while announcing plans to divest its immunodiagnostics business in China as it sharpens its portfolio.

 

The life sciences and diagnostics company posted second-quarter revenue of $730 million, up from $720 million a year earlier, while GAAP earnings per share from continuing operations edged up to $0.48 from $0.47. Adjusted earnings per share climbed to $1.41, compared with $1.18 in the prior-year period, as adjusted operating income increased to $211 million from $192 million.

 

GAAP operating income from continuing operations was $89 million, including $16 million in tariff-related refunds, compared with $91 million a year ago. Adjusted operating margin improved to 28.9% from 26.6%.

 

The company also announced it has entered into a definitive agreement to divest its China Immunodiagnostics (China IDX) business, which accounted for about 6% of total 2025 revenue. The transaction is expected to close by the end of 2027, subject to customary closing conditions and regulatory approvals. Revvity said all forward-looking guidance is being provided on a pro forma basis excluding the China business.

 

On a pro forma basis, second-quarter revenue rose to $711 million from $681 million a year earlier, while operating income increased to $94 million from $85 million. Pro forma earnings per share from continuing operations improved to $0.52 from $0.48.

 

Pro forma adjusted earnings per share came in at $1.41, including approximately $0.11 from tariff-related refunds, up from $1.15 a year ago. Pro forma adjusted operating income rose to $209 million, including $16 million in tariff-related refunds, compared with $180 million in the prior-year quarter, while adjusted operating margin expanded to 29.3% from 26.5%.

 

“Revvity delivered a strong second quarter, with results above our expectations and encouraging signs of increased demand across our customer base,” said Prahlad Singh, president and chief executive officer of Revvity. 

 

"As we enter the second half of the year, given the clear momentum in our end markets, we are utilizing a portion of recently received tariff refunds to increase investments across the business, capitalize on emerging opportunities, and support future growth.”

 

By segment, the Life Sciences business generated $359 million in revenue, down from $366 million a year ago, with pro forma organic revenue declining 3%. Adjusted operating income was $112 million, compared with $115 million in the prior-year quarter.

 

The Diagnostics segment outperformed, with revenue rising to $371 million from $354 million a year earlier. Pro forma organic revenue increased 11%, while adjusted operating income jumped to $113 million from $89 million. Adjusted operating margin expanded to 30.4%, up from 25.2%.

 

Looking ahead, Revvity expects full-year 2026 pro forma revenue of $2.83 billion to $2.86 billion, pro forma organic revenue growth of 4% to 5%, and pro forma adjusted earnings per share of $5.30 to $5.40.